Breaking News Instant updates and real-time market news.

RAD

Rite Aid

$10.76

1.116 (11.57%)

, ZYNE

Zynerba

$9.49

1.39 (17.16%)

08:45
04/23/19
04/23
08:45
04/23/19
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Rite Aid (RAD) 8.18% +4.31, Zynerba (ZYNE) 18.40% +0.39, Coty (COTY) 2.26% +0.31, Pyxus International (PYX) 8.08% +0.08, Hormel Foods (HRL) 0.44% +0.06, Papa John's (PZZA) 3.43% +0.06, Kandi Technologies (KNDI) 17.55% +0.05, UBS (UBS) 0.41% +0.05, BHP Billiton (BHP) 0.81% +0.04, and Qutoutiao (QTT) 6.66% +0.04.

RAD

Rite Aid

$10.76

1.116 (11.57%)

ZYNE

Zynerba

$9.49

1.39 (17.16%)

COTY

Coty

$11.22

-0.05 (-0.44%)

PYX

Pyxus

$21.00

3.63 (20.90%)

HRL

Hormel Foods

$40.44

0.06 (0.15%)

PZZA

Papa John's

$49.25

-0.05 (-0.10%)

KNDI

Kandi Technologies

$5.40

-0.03 (-0.55%)

UBS

UBS

$13.26

0.005 (0.04%)

BHP

BHP Group

$55.14

0.19 (0.35%)

QTT

Qutoutiao

$9.00

(0.00%)

  • 25

    Apr

  • 30

    Apr

  • 18

    May

  • 20

    May

  • 28

    May

  • 29

    May

  • 03

    Jun

  • 13

    Nov

RAD Rite Aid
$10.76

1.116 (11.57%)

04/18/19
04/18/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Morgan Stanley (MS) downgraded to Neutral from Buy at Citi with analyst Keith Horowitz saying Morgan Stanley reported "strong" Q1 results but the shares are fairly valued. 2. Snap (SNAP) downgraded to Negative from Mixed at Vertical Group and to Neutral from Outperform at Wedbush. 3. Rite Aid (RAD) downgraded with a Sell from Neutral at Guggenheim while Walgreens Boots Alliance (WBA) was downgraded with a Neutral from Buy. 4. CF Industries (CF) downgraded to Underperform from Buy at BofA/Merrill with analyst Steve Byrne saying he has spoken with 10 key channel contacts in the Cornbelt and several commented that never in their 30-plus year careers have they seen fertilizer applications this far behind, mainly due to the weather. 5. FMC Corporation (FMC) downgraded to Sector Perform from Outperform at RBC Capital with analyst Arun Viswanathan citing the "uncertainty of Rynaxypyr and Cyazypyr patent expiration" as well as the reduced multiple from the recent lithium separation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/17/19
GUGG
04/17/19
DOWNGRADE
GUGG
Sell
Rite Aid assumed with a Sell from Neutral at Guggenheim
12/20/18
LOOP
12/20/18
NO CHANGE
Target $1
LOOP
Hold
Rite Aid price target lowered to $1.00 at Loop Capital
Loop Capital analyst Andrew Wolf lowered his price target on Rite Aid to $1.00 from $1.35 and kept his Hold rating after its Q3 results. The analyst notes that while the company beat on earnings, it brought down the midpoint of its FY19 guidance, which suggests that the company is not yet an an operational inflection point. Wolf adds that while the stock trades at a discount to the drugstore group, he sees it as appropriate given the "higher debt leverage and subscale operations."
04/17/19
GUGG
04/17/19
DOWNGRADE
GUGG
Sell
Rite Aid assumed with a Sell from Neutral at Guggenheim
Guggenheim analyst Glen Santangelo assumed coverage of Rite Aid and downgraded the shares to Sell from the firm's Neutral rating under analyst John Heinbockel. Santangelo also lowered the price target fro Rite Aid to 35c per share, down from 45c per share. The analyst believes Rite Aid's "significant debt burden" and "high leverage will continue to limit Rite Aid's ability to work through its structural and competitive issues."
ZYNE Zynerba
$9.49

1.39 (17.16%)

07/05/18
HCWC
07/05/18
NO CHANGE
Target $23
HCWC
Buy
Zynerba failed program not material negative, says H.C. Wainwright
Zynerba Pharmaceuticals this morning announced it is discontinuing development of its transdermal THC pro-drug patch ZYN001 after a Phase 1 study in healthy subjects failed to deliver the targeted potential therapeutic blood levels. This development is not a material negative, H.C. Wainwright analyst Oren Livnat tells investors in a research note. The analyst says he never included ZYN001 for Tourette's or any other indication in his estimates or valuation. He notes that his valuation is entirely based on orphan designated ZYN002 transdermal cannabidiol gel for Fragile X syndrome, entering Phase 3 shortly, "with upside optionality from ongoing work in refractory and rare epilepsies." Livnat views the early-stage ZYN001 termination "as a sign of responsible drug development" and keeps a Buy rating on Zynerba with a $23 price target. The stock in afternoon trading is down 54c to $9.07.
08/06/18
HCWC
08/06/18
NO CHANGE
Target $23
HCWC
Buy
Zynerba 46% pullback since financing unwarranted, says H.C. Wainwright
Shares of Zynerba Pharmaceuticals are down 46% since the company announced a $30M financing late July, and down 30% from where it priced at $8 per share, H.C. Wainwright analyst Oren Livnat tell investors in a research note. The analyst views the stock weakness as unwarranted. The ZYN002 programs are on track for key 2019 readouts, Livnat points out. He believes Zynerba's current valuation "belies even highly risk-discounted opportunities." The analyst is "perplexed by the extreme ZYNE pullback." Livnat says he's not aware of any erosion of Zynerba's fundamentals or prospects. The analyst reiterates aBuy rating on Zynerba with a $23 price target.
09/21/18
CANT
09/21/18
INITIATION
Target $21
CANT
Overweight
Zynerba initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan last night initiated coverage of Zynerba with an Overweight rating and $21 price target. The analyst, who started coverage on seven Neuro-Innovator and Platform-Enabled Therapeutic companies, believes that "biotech has entered a golden age of innovation and productivity across many therapeutic areas."
04/22/19
ADAM
04/22/19
INITIATION
Target $18
ADAM
Buy
Zynerba assumed with a Buy at Canaccord
Canaccord analyst Sumant Kulkarni assumed coverage of Zynerba Pharmaceuticals with a Buy rating and $18 price target. In a research note to investors, Kulkarni says he believes Zynerba, with Zygel's multiple shots on goal, presents significant opportunity for risk-tolerant investors heading into key events, including data for an open-label Phase 2 trial in developmental and epileptic encephalopathies in the third quarter of 2019, and data for a trial for Fragile X syndrome in the second half of the year.
COTY Coty
$11.22

-0.05 (-0.44%)

04/17/19
04/17/19
DOWNGRADE
Target $12

Hold
Coty downgraded to Hold from Buy at Stifel
As previously reported, Stifel analyst Mark Astrachan downgraded Coty to Hold and kept his price target at $12, saying the stock is faced with an "increased risk of sustaining modest sales growth and weakening investor confidence in the business turnaround." While the analyst anticipates "only minor residual impact" from supply disruptions on Q3 results, he sees the outlook for Consumer Beauty remaining muted and also points to the company's debt levels and free cash flows limiting its strategic optionality.
04/17/19
STFL
04/17/19
DOWNGRADE
STFL
Hold
Coty downgraded to Hold from Buy at Stifel
04/16/19
04/16/19
UPGRADE
Target $15

Buy
e.l.f. Beauty upgraded to Buy at DA Davidson on increased shelf space presence
As previously reported, DA Davidson analyst Linda Bolton Weiser upgraded e.l.f. Beauty to Buy from Hold and raised her price target to $15 from $7. The analyst cites the findings of her proprietary store checks suggesting that the company products have seen a 17% increase in shelf space at Target (TGT), overtaking Coty's (COTY) Covergirl brand, while its Q1 sales "inflected from down high-single digits" in Q4 to low-single digits. Weiser believes that her FY20 sales forecast of a 2% decline may be conservative based on these findings.
04/02/19
SBSH
04/02/19
DOWNGRADE
Target $12
SBSH
Neutral
Coty downgraded to Neutral from Buy at Citi
Citi analyst Wendy Nicholson downgraded Coty to Neutral from Buy and lowered her price target for the shares to $12 from $13. The analyst cites valuation for the downgrade following the stock's year-to-date rally.
PYX Pyxus
$21.00

3.63 (20.90%)

HRL Hormel Foods
$40.44

0.06 (0.15%)

04/23/19
GSCO
04/23/19
DOWNGRADE
GSCO
Sell
Goldman downgrades Hormel to Sell, upgrades Sanderson to Neutral
Goldman Sachs analyst Adam Samuelson downgraded Hormel Foods (HRL) to Sell from Neutral and cut his price target for the shares to $35 from $37. With his estimates now below consensus and "limited" earnings growth forecasted through fiscal 2020, the analyst sees risk to Hormel's "premium" valuation. The breadth and depth of African swine fever's impact across the Chinese pork industry, and as a result the global protein industry, will be significant in the near-to-medium-term, Samuelson tells investors in a research note. Buy-rated Tyson Foods (TSN) and BRF S.A. (BRFS) remain the analyst's preferred way to gain exposure to the Global Protein market. Samuelson this morning also upgraded Sanderson Farms (SAFM) to Neutral from Sell and raised his price target for the shares for $131 from $81. Higher competing protein prices and improving U.S. export prospects "make a more negative stance unsustainable," Samuelson contends. He raised his fiscal 2020 and 2021 margin forecasts for the company to "normalized levels." However, further upside is tempered, for now, by increases in U.S. processing capacity coming on stream over the next 18 months, the analyst contends.
04/23/19
GSCO
04/23/19
DOWNGRADE
Target $35
GSCO
Sell
Hormel Foods downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Adam Samuelson downgraded Hormel Foods to Sell from Neutral and lowered his price target for the shares to $35 from $37. African swine fever is upending the protein markets, Samuelson tells investors in a research note. JPMorgan this morning also downgraded Hormel Foods to a sell-equivalent rating.
04/23/19
JPMS
04/23/19
DOWNGRADE
Target $36
JPMS
Underweight
Hormel Foods downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Thomas Palmer downgraded Hormel Foods to Underweight from Neutral and lowered his price target for the shares to $36 from $40.
04/23/19
JPMS
04/23/19
DOWNGRADE
Target $36
JPMS
Underweight
JPMorgan downgrades Hormel Foods to Underweight on rising pork costs
JPMorgan analyst Thomas Palmer downgraded Hormel Foods to Underweight from Neutral and lowered his price target for the shares to $36 from $40. Goldman Sachs this morning also downgraded the shares. Rising pork costs and worsening Jennie-O ground turkey brand distribution points could weigh on Hormel's earnings, Palmer tells investors in a research note. Hormel is heavily reliant upon pork as an input for its products, and the company will likely be able to fully offset these cost increases through pricing, Palmer tells investors in a research note. African swine fever in China could result in an extended period of elevated pork pricing in the U.S., he contends.
PZZA Papa John's
$49.25

-0.05 (-0.10%)

04/01/19
KERI
04/01/19
UPGRADE
KERI
Buy
Papa John's upgraded to Buy from Neutral at Kalinowski
02/27/19
SPHN
02/27/19
NO CHANGE
Target $55
SPHN
Overweight
Papa John's guidance better than feared, says Stephens
Stephens analyst Will Slabaugh said Papa John's February update was "somewhat encouraging" and that the company's guidance for FY19 was "better than feared." While he expects sales and margins to remain pressured throughout 2019, Slabaugh thinks market expectations are for a choppy recovery and the quarterly report "helped to keep the hope for $2.00 in EPS power alive," he tells investors. He maintains an Overweight rating and $55 price target on Papa John's shares.
03/27/19
03/27/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Bed Bath & Beyond (BBBY) upgraded to Hold from Sell at Loop Capital with analyst Anthony Chukumba citing the recent proxy contest threat was posed by an activist hedge fund consortium amassing 5% of the company stock. 2. Papa John's (PZZA) upgraded to Hold from Sell at Stifel with analyst Chris O'Cull saying he believes the company's turnaround has entered a phase where investors believe the worst is behind it "and are willing to accord the company a hall pass to see whether the sales plan can work." 3. ON Semiconductor (ON) upgraded to Buy from Neutral at Goldman Sachs with analyst Mark Delaney saying while not immune to cyclical risks, ON has improved its exposure to secular opportunities in advanced driver assistance system image sensors, electric vehicles and the cloud. 4. Ralph Lauren (RL) upgraded to Outperform from Market Perform at Wells Fargo with analyst Ike Boruchow saying he views the company as a "rare standout" in his space, with increased visibility, running ahead of plan and with the potential for accelerating growth in the years ahead. 5. Lumentum (LITE) upgraded to Overweight from Equal Weight at Morgan Stanley. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/27/19
STFL
03/27/19
UPGRADE
Target $45
STFL
Hold
Papa John's upgraded to Hold from Sell at Stifel
Stifel analyst Chris O'Cull upgraded Papa John's International to Hold from Sell and raised his price target for the shares to $45 from $35. The analyst believes the company's turnaround has entered a phase where investors believe the worst is behind it "and are willing to accord the company a hall pass to see whether the sales plan can work." The more optimistic sentiment stems from the view that the new board of directors and new brand spokesperson Shaquille O'Neal can reverse the declining traffic and EBITDA trends, O'Cull tells investors in a research note titled "Sell Thesis Not a Slam Dunk; Investors Optimism Outweighing Fundamentals." The analyst remains concerned that low franchisee profits will require ongoing financial support from Papa John's and declining transactions will pressure commissary profits, but he believes investor optimism will likely outweigh these fundamental issues in the near-term.
KNDI Kandi Technologies
$5.40

-0.03 (-0.55%)

UBS UBS
$13.26

0.005 (0.04%)

03/26/19
KBWI
03/26/19
DOWNGRADE
KBWI
Market Perform
UBS downgraded to Market Perform from Outperform at Keefe Bruyette
01/08/19
01/08/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Unilever (UN, UL) downgraded to Neutral from Buy at UBS. 2. General Dynamics (GD) downgraded to Hold from Buy at Jefferies with analyst Sheila Kahyaoglu saying despite a portfolio of "marquee assets," the company's earnings "lack momentum." 3. Principal Financial (PFG) downgraded to Neutral from Buy at Goldman Sachs with analyst Alex Scott saying he sees less upside in the shares relative to other names in his life insurance coverage universe. 4. JPMorgan (JPM), SunTrust (STI), and U.S. Bancorp (USB) were downgraded to Hold from Buy at Jefferies. 5. Maxar Technologies (MAXR) downgraded to Underperform from Neutral at Credit Suisse, to Sell at Veritas, to Market Perform from Outperform at BMO Capital, and to Sector Perform at National Bank. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/09/19
SOCG
01/09/19
DOWNGRADE
SOCG
Hold
UBS downgraded to Hold from Buy at Societe Generale
03/26/19
KBWI
03/26/19
DOWNGRADE
Target $13.5
KBWI
Market Perform
KBW sees 'tapered' buybacks for UBS, downgrades shares to Market Perform
UBS analyst Thomas Hallett downgraded UBS to Market Perform from Outperform and lowered his price target for the shares to $13.50 from $15.00. The stock in midday trading is up 5c to $11.86. After analyzing the events between UBS and Swiss regulator FINMA, the analyst reduced his estimates to reflect additional provisions for litigation. Hallett believes FINMA will require a temporary operational risk weight add-on in relation to litigation matters through a "staged approach." This will keep UBS' buybacks operational, "but tapered in nature," the analyst tells investors in a research note.
BHP BHP Group
$55.14

0.19 (0.35%)

02/19/19
GSCO
02/19/19
DOWNGRADE
GSCO
Neutral
BHP Group downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Paul Young downgraded BHP Group to Neutral from Buy after the company reported 1H FY19 underlying earnings that were down 23% half-over-half due to a weak operating performance mainly across copper and coal. The company's production, capex, growth projects and unit costs guidance implies a very strong operating performance in the second half, said Young, who cites valuation for his rating change. He decreased his FY19 EPS estimate by 4% on the slightly weaker result and higher thermal coal costs and revised his price target on BHP shares to A$36.20.
04/22/19
UBSW
04/22/19
DOWNGRADE
UBSW
Neutral
BHP Group downgraded to Neutral from Buy at UBS
03/07/19
SOCG
03/07/19
DOWNGRADE
SOCG
Hold
BHP Group downgraded to Hold from Buy at Societe Generale
04/23/19
UBSW
04/23/19
DOWNGRADE
UBSW
Neutral
BHP Group downgraded to Neutral from Buy at UBS
UBS analyst Glyn Lawcock last night downgraded BHP Group to Neutral from Buy with an unchanged price target of 1,900 pence. The stock's rally has been supported by higher iron ore prices, but these should fall over the next six to 12 months, Lawcock tells investors in a research note. The analyst expects prices of both iron and thermal coal to moderate.
QTT Qutoutiao
$9.00

(0.00%)

03/06/19
KEYB
03/06/19
DOWNGRADE
KEYB
Sector Weight
Qutoutiao downgraded to Sector Weight from Overweight at KeyBanc
02/20/19
DBAB
02/20/19
DOWNGRADE
DBAB
Hold
Qutoutiao downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Hanjoon Kim downgraded Qutoutiao to Hold saying the risk/reward is balanced at current share levels.
02/15/19
UBSW
02/15/19
DOWNGRADE
Target $13.5
UBSW
Neutral
Qutoutiao downgraded to Neutral from Buy at UBS
UBS analyst Jerry Liu downgraded Qutoutiao to Neutral from Buy, telling investors in a research note that the share price has almost tripled since mid-December, possibly attributable to the strong momentum of the company's user expansion as well as Midu's initial success. Liu, who raised his price target to $13.50 from $11, says Qutoutiao's current price implies 2.8x2019E P/S, which he thinks represents a fair risk-reward balance between its user growth potential and margin pressure.
04/16/19
SBSH
04/16/19
UPGRADE
Target $14
SBSH
Buy
Qutoutiao upgraded to Buy from Neutral at Citi
Citi analyst Alicia Yap upgraded Qutoutiao to Buy from Neutral while lowering her price target for the shares to $14 from $16. The analyst sees a better risk/reward profile with the shares down 24% since the March 29 secondary offering. Qutoutiao's user numbers were solid in March and possible further collaborations with Taobao merchants and Alibaba's marketing could allow the company to capitalize on user retention, Yap tells investors in a research note

TODAY'S FREE FLY STORIES

XOG

Extraction Oil & Gas

$3.89

-0.27 (-6.49%)

17:10
07/17/19
07/17
17:10
07/17/19
17:10
Hot Stocks
Morgan Stanley reports 5% passive stake in Extraction Oil & Gas »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

SMTX

SMTC Corp.

$3.98

-0.02 (-0.50%)

17:10
07/17/19
07/17
17:10
07/17/19
17:10
Syndicate
Breaking Syndicate news story on SMTC Corp. »

SMTC Corp. files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCK

Crown Holdings

$59.38

-0.88 (-1.46%)

17:08
07/17/19
07/17
17:08
07/17/19
17:08
Hot Stocks
Breaking Hot Stocks news story on Crown Holdings »

Crown Holdings down 1.4%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

CCK

Crown Holdings

$59.38

-0.88 (-1.46%)

17:07
07/17/19
07/17
17:07
07/17/19
17:07
Earnings
Crown Holdings sees FY19 EPS $5.05-$5.20, consensus $5.28 »

The company said the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

ASH

Ashland

$77.77

-0.64 (-0.82%)

17:06
07/17/19
07/17
17:06
07/17/19
17:06
Earnings
Ashland cuts FY19 adjusted EBITDA for Specialty Ingredients to $560M-$570M »

Prior view was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 16

    Aug

W

Wayfair

$151.93

1.965 (1.31%)

17:05
07/17/19
07/17
17:05
07/17/19
17:05
Hot Stocks
Wayfair COO James Savarese, CTO John Mulliken to retire »

Wayfair announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 05

    Aug

CCK

Crown Holdings

$59.38

-0.88 (-1.46%)

17:05
07/17/19
07/17
17:05
07/17/19
17:05
Earnings
Breaking Earnings news story on Crown Holdings »

Crown Holdings sees Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

ASH

Ashland

$77.77

-0.64 (-0.82%)

17:03
07/17/19
07/17
17:03
07/17/19
17:03
Earnings
Ashland sees Q3 EPS 76c-78c, consensus 86c »

Sees Q3 adjusted EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 16

    Aug

CCK

Crown Holdings

$59.38

-0.88 (-1.46%)

17:03
07/17/19
07/17
17:03
07/17/19
17:03
Earnings
Crown Holdings reports Q2 EPS $1.46, consensus $1.47 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

HOV

Hovnanian

$8.58

-0.27 (-3.05%)

17:01
07/17/19
07/17
17:01
07/17/19
17:01
Hot Stocks
Hovnanian receives continued listing standard notice from NYSE »

Hovnanian Enterprises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UPS

UPS

$102.21

-3.4 (-3.22%)

, JBLU

JetBlue

$19.09

-0.42 (-2.15%)

17:01
07/17/19
07/17
17:01
07/17/19
17:01
Hot Stocks
JetBlue names Teri McClure to Board of Directors »

JetBlue (JBLU) announced…

UPS

UPS

$102.21

-3.4 (-3.22%)

JBLU

JetBlue

$19.09

-0.42 (-2.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 24

    Jul

SON

Sonoco

$63.70

-0.38 (-0.59%)

16:58
07/17/19
07/17
16:58
07/17/19
16:58
Hot Stocks
Sonoco to terminate U.S. defined benefit pension plan for inactive participants »

Sonoco announced its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 06

    Aug

  • 17

    Oct

PEP

PepsiCo

$132.77

-1.04 (-0.78%)

, AAP

Advance Auto Parts

$157.70

-4.135 (-2.56%)

16:53
07/17/19
07/17
16:53
07/17/19
16:53
Hot Stocks
Advance Auto Parts names Jason McDonnell as Chief Marketing Officer »

Advance Auto Parts (AAP)…

PEP

PepsiCo

$132.77

-1.04 (-0.78%)

AAP

Advance Auto Parts

$157.70

-4.135 (-2.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

CSX

CSX

$71.37

-8.2 (-10.31%)

, AMZN

Amazon.com

$1,992.41

-17.59 (-0.88%)

16:49
07/17/19
07/17
16:49
07/17/19
16:49
On The Fly
Fly Intel: Wall Street's top stories for Wednesday »

Stocks spent the day…

CSX

CSX

$71.37

-8.2 (-10.31%)

AMZN

Amazon.com

$1,992.41

-17.59 (-0.88%)

BAC

Bank of America

$29.18

0.19 (0.66%)

ABT

Abbott

$85.78

2.67 (3.21%)

MSFT

Microsoft

$136.23

-0.85 (-0.62%)

T

AT&T

$33.26

-0.31 (-0.92%)

NLNK

NewLink Genetics

$1.44

-0.015 (-1.03%)

MRK

Merck

$81.93

0.36 (0.44%)

MTSI

Macom

$17.57

2.02 (12.99%)

SGEN

Seattle Genetics

$75.22

12.1 (19.17%)

INO

Inovio

$2.71

-0.29 (-9.67%)

NUS

Nu Skin

$38.87

-6.63 (-14.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 18

    Jul

  • 24

    Jul

  • 25

    Jul

  • 30

    Jul

  • 30

    Jul

  • 06

    Aug

  • 06

    Aug

  • 06

    Aug

  • 08

    Aug

  • 08

    Aug

  • 26

    Aug

  • 06

    Sep

  • 09

    Sep

  • 16

    Sep

  • 20

    Sep

  • 02

    Oct

  • 13

    Nov

AZRX

AzurRx BioPharma

$1.06

-0.05 (-4.50%)

16:45
07/17/19
07/17
16:45
07/17/19
16:45
Syndicate
AzurRx BioPharma files to sell common stock, no amount given »

H.C. Wainwright & Co.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MICR

Micron Solutions

$2.55

(0.00%)

16:44
07/17/19
07/17
16:44
07/17/19
16:44
Hot Stocks
Micron Solutions names Wayne M. Coll CFO »

Micron Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSX

CSX

$71.37

-8.2 (-10.31%)

, GWR

Genesee & Wyoming

$109.64

-0.36 (-0.33%)

16:42
07/17/19
07/17
16:42
07/17/19
16:42
Periodicals
U.S freight rail declines indicate economic weakness, FT says »

According to the…

CSX

CSX

$71.37

-8.2 (-10.31%)

GWR

Genesee & Wyoming

$109.64

-0.36 (-0.33%)

UNP

Union Pacific

$164.05

-11.05 (-6.31%)

CP

Canadian Pacific

$244.53

-1.74 (-0.71%)

KSU

Kansas City Southern

$116.81

-6.02 (-4.90%)

NSC

Norfolk Southern

$191.17

-15.36 (-7.44%)

CNI

Canadian National

$92.60

-2.67 (-2.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 19

    Jul

  • 23

    Jul

  • 24

    Jul

  • 26

    Aug

  • 13

    Nov

16:41
07/17/19
07/17
16:41
07/17/19
16:41
Conference/Events
House Judiciary Committee to hold a hearing »

The Subcommittee on…

CODYY

Saint-Gobain

$0.00

(0.00%)

16:41
07/17/19
07/17
16:41
07/17/19
16:41
Initiation
Saint-Gobain initiated  »

Saint-Gobain initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWK

Stanley Black & Decker

$142.78

-4.335 (-2.95%)

16:41
07/17/19
07/17
16:41
07/17/19
16:41
Hot Stocks
Stanley Black & Decker raises quarterly dividend to 69c from 66c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 01

    Aug

AZRE

Azure Power

$10.61

0.16 (1.53%)

16:35
07/17/19
07/17
16:35
07/17/19
16:35
Hot Stocks
Azure Power names Ranjit Gupta as new CEO »

Azure Power announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEGH

Legacy Housing

$12.79

-0.01 (-0.08%)

16:35
07/17/19
07/17
16:35
07/17/19
16:35
Hot Stocks
Legacy Housing appoints Cornelius Van Den Handel CFO »

Legacy Housing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REI

Ring Energy

$3.05

-0.085 (-2.72%)

16:33
07/17/19
07/17
16:33
07/17/19
16:33
Hot Stocks
Ring Energy provides Q2 operations update »

Ring Energy released its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:33
07/17/19
07/17
16:33
07/17/19
16:33
Conference/Events
Federal Reserve Bank of New York president delivers keynote address »

New York Federal Reserve…

ECOL

US Ecology

$61.95

1.14 (1.87%)

, NRCG

NRC Group

$11.81

0.03 (0.25%)

16:33
07/17/19
07/17
16:33
07/17/19
16:33
Hot Stocks
US Ecology, NRC Group granted early termination of HSR waiting period »

The Federal Trade…

ECOL

US Ecology

$61.95

1.14 (1.87%)

NRCG

NRC Group

$11.81

0.03 (0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.